XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(Q1)Sep 30, 2024 | (FY)Jun 30, 2024 | (Q4)Jun 30, 2024 | (Q3)Mar 31, 2024 | (Q2)Dec 31, 2023 | (Q1)Sep 30, 2023 | (FY)Jun 30, 2023 | (Q4)Jun 30, 2023 | (Q3)Mar 31, 2023 | (Q2)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -37.95%13.32M | -10.54%85.67M | 15.19%125.86M | -127.96%-15.12M | 24.35%-46.53M | 455.17%21.46M | -0.62%95.77M | 165.69%109.26M | 133.24%54.06M | -95.31%-61.51M |
Net income from continuing operations | 104.96%1.63M | -301.31%-130.72M | -2,235.39%-41.57M | -1,371.54%-83.57M | 194.10%27.22M | 4.56%-32.8M | 78.23%-32.57M | 98.06%-1.78M | 84.19%-5.68M | 547.75%9.26M |
Operating gains losses | -625.36%-54.92M | 30.48%-26.67M | 55.16%-7.63M | 129.65%3.21M | 3.74%-14.68M | -260.46%-7.57M | -381.62%-38.36M | -190.82%-17.01M | -254.20%-10.82M | -1,094.13%-15.25M |
Depreciation and amortization | 12.91%57.53M | 10.78%206.65M | 5.64%50.65M | 8.66%50.41M | 12.49%54.65M | 16.81%50.95M | 12.52%186.53M | 14.83%47.95M | 7.97%46.39M | 15.03%48.58M |
Other non cash items | 4.10%12.82M | 23.65%52.66M | -11.42%11.18M | 23.31%13.73M | 46.95%15.42M | 47.94%12.32M | 63.41%42.59M | 55.90%12.63M | 81.28%11.14M | 76.46%10.5M |
Change In working capital | 157.62%5.78M | 147.20%14.67M | 61.12%120.58M | -44.10%13.21M | -9.99%-121.36M | 111.69%2.24M | -147.33%-31.08M | 9.39%74.84M | 115.36%23.62M | -49.82%-110.34M |
-Change in receivables | -78.45%-19.64M | 45.92%13.11M | -44.22%18.07M | 16.87%50.01M | 38.87%-43.97M | -292.29%-11.01M | 235.61%8.98M | 32.43%32.4M | 212.68%42.79M | -79.15%-71.93M |
-Change in inventory | -373.05%-8.9M | 60.83%-378K | 141.15%214K | -57.42%267K | 112.92%1.02M | -21.20%-1.88M | -704.17%-965K | -205.69%-520K | 240.76%627K | 557.14%480K |
-Change in prepaid assets | 10.05%-18.1M | -1.29%-1.73M | -418.75%-415K | 2.34%9.52M | 100.22%9.29M | -29.25%-20.12M | 80.69%-1.7M | 97.99%-80K | 4.43%9.3M | -2.89%4.64M |
-Change in payables and accrued expense | 395.08%24.31M | 39.29%-18.9M | 1,398.63%10.96M | -61.21%1.98M | -19.08%-23.6M | 51.98%-8.24M | -238.52%-31.14M | -95.74%731K | -44.36%5.1M | -58.16%-19.82M |
-Change in other working capital | -35.36%28.11M | 461.01%22.57M | 116.87%91.76M | -42.01%-48.58M | -170.38%-64.09M | 365.24%43.49M | -112.64%-6.25M | 39.76%42.31M | -63.01%-34.21M | 7.53%-23.7M |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -37.95%13.32M | -10.54%85.67M | 15.19%125.86M | -127.96%-15.12M | 24.35%-46.53M | 455.17%21.46M | -0.62%95.77M | 165.69%109.26M | 133.24%54.06M | -95.31%-61.51M |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -12.89%-130.47M | -22.15%-171.2M | -12.22%-6.13M | -64.97%-18.88M | -0.41%-30.63M | -24.60%-115.57M | -50.01%-140.16M | 10.73%-5.46M | -192.36%-11.44M | -63.49%-30.5M |
Net PPE purchase and sale | -14.07%-10.3M | -12.17%-17.51M | 55.79%-2.56M | -14.43%-3.11M | -3.88%-2.81M | -105.53%-9.03M | -87.56%-15.61M | -175.95%-5.8M | -276.84%-2.72M | -44.40%-2.71M |
Net intangibles purchase and sale | -12.79%-120.17M | -23.40%-153.69M | -1,160.71%-3.56M | -80.71%-15.77M | -0.07%-27.82M | -20.58%-106.54M | -46.34%-124.55M | 108.37%336K | -173.29%-8.73M | -65.63%-27.8M |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -12.89%-130.47M | -22.15%-171.2M | -12.22%-6.13M | -64.97%-18.88M | -0.41%-30.63M | -24.60%-115.57M | -50.01%-140.16M | 10.73%-5.46M | -192.36%-11.44M | -63.49%-30.5M |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 100.27%199.87M | 4,517.57%86.23M | -11.24%-111.63M | 25,173.20%38.36M | -39.96%59.7M | 11,466.74%99.8M | -138.73%-1.95M | -728.31%-100.35M | 98.65%-153K | 151.29%99.43M |
Net issuance payments of debt | 100.27%199.87M | -3,536.07%-70.98M | -9.91%-110.3M | -78,449.02%-120.18M | -39.96%59.7M | 11,466.74%99.8M | -105.06%-1.95M | -81,485.37%-100.35M | 64.91%-153K | 151.29%99.43M |
Net common stock issuance | ---- | --158.54M | --0 | --158.54M | ---- | ---- | --0 | --0 | --0 | ---- |
Cash dividends paid | ---- | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- |
Net other financing activities | ---- | ---1.34M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 100.27%199.87M | 4,517.57%86.23M | -11.24%-111.63M | 25,173.20%38.36M | -39.96%59.7M | 11,466.74%99.8M | -138.73%-1.95M | -728.31%-100.35M | 98.65%-153K | 151.29%99.43M |
Net cash flow | ||||||||||
Beginning cash position | -3.25%73.55M | -37.29%76.02M | -9.14%66.99M | 102.32%62.81M | 232.94%80.83M | -37.29%76.02M | 9.55%121.22M | -23.03%73.73M | -64.49%31.05M | -75.39%24.28M |
Current changes in cash | 1,353.74%82.72M | 101.51%698K | 134.92%8.1M | -89.72%4.37M | -335.39%-17.46M | 105.71%5.69M | -680.74%-46.34M | -84.94%3.45M | 435.00%42.47M | 170.09%7.42M |
Effect of exchange rate changes | -662.39%-6.71M | -378.14%-3.17M | -32.96%-1.55M | -182.73%-182K | 13.56%-561K | -132.23%-880K | -55.94%1.14M | -145.75%-1.16M | -47.49%220K | 0.15%-649K |
End cash Position | 85.03%149.56M | -3.25%73.55M | -3.25%73.55M | -9.14%66.99M | 102.32%62.81M | 232.94%80.83M | -37.29%76.02M | -37.29%76.02M | -23.03%73.73M | -64.49%31.05M |
Free cash flow | -25.83%-150.72M | -61.25%-122.56M | 29.30%118.97M | -200.43%-36.68M | 9.58%-85.07M | -8.44%-119.78M | -177.73%-76.01M | 268.92%92.01M | 203.35%36.52M | -80.64%-94.08M |
Currency Unit | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP | GBP |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- |